How a once-failed drug became a new hope for Alzheimer’s
An underdog Alzheimer's pill, ALZ-801, showed promise in a subgroup of mild cognitive impairment patients, slowing decline by 52% and hippocampal atrophy by 18%. This oral treatment offers a convenient, upstream approach to amyloid formation, potentially avoiding ARIA side effects seen with antibody infusions, especially for APOE4 carriers.
An underdog Alzheimer's pill, ALZ-801, showed promise in a subgroup of mild cognitive impairment patients, slowing decline by 52% and hippocampal atrophy by 18%. This oral treatment offers a convenient, upstream approach to amyloid formation, potentially avoiding ARIA side effects seen with antibody infusions, especially for APOE4 carriers.
